1. Report Introduction 2. Achondroplasia (Achondroplastic dwarfism) 2.1. Achondroplasia Disease Overview 2.2. Achondroplasia History 2.3. Achondroplasia Symptoms 2.4. Achondroplasia Causes 2.5. Achondroplasia Pathophysiology 2.6. Achondroplasia Diagnosis 2.6.1. Diagnostic Guidelines 3. Achondroplasia Current Treatment Patterns 3.1. Treatment Guidelines 4. Achondroplasia - DelveInsight’s Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Achondroplasia companies collaborations, Licensing, Acquisition –Deal Value Trends 4.1.1.1. Assessment Summary 4.1.2. Achondroplasia Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis 4.1.2.2. Achondroplasia Acquisition Analysis 4.2. Clinical Assessment of Pipeline Drugs 4.2.1. Assessment by Phase of Development 4.2.2. Assessment by Product Type (Mono / Combination) 4.2.2.1. Assessment by Stage and Product Type 4.2.3. Assessment by Route of Administration 4.2.3.1. Assessment by Stage and Route of Administration 4.2.4. Assessment by Molecule Type 4.2.4.1. Assessment by Stage and Molecule Type 4.2.5. Assessment by MOA 4.2.5.1. Assessment by Stage and MOA 5. Achondroplasia Pipeline Therapeutics 5.1. Late Stage Products (Phase-III) 5.1.1. Comparative Analysis 5.2. Mid Stage Products (Phase-II) 5.2.1. Comparative Analysis 5.3. Early Stage Products (Phase-I) 5.3.1. Comparative Analysis 5.4. Pre-clinical and Discovery Stage Products 5.4.1. Comparative Analysis 5.5. Inactive Products 6. Achondroplasia -Products Analysis 6.1. Product Profiles 6.1.1. Vosoritide : BioMarin Pharmaceutical 6.1.1.1. Product Description 6.1.1.1.1. Product Overview 6.1.1.1.2. Mechanism of Action 6.1.1.2. Research and Development 6.1.1.2.1. Clinical Studies 6.1.1.2.1.1. Detailed Study Description 6.1.1.2.1.2. Study Results 6.1.1.2.1.3. Clinical Trials: Tabular View 6.1.1.3. Product Development Activities 6.1.1.3.1. Tabulated Product Summary 6.1.1.3.1.1. General Description Table 6.1.2. Vofatamab: Rainier Therapeutics 6.1.2.1. Product Description 6.1.2.1.1. Product Overview 6.1.2.1.2. Mechanism of Action 6.1.2.2. Research and Development 6.1.2.2.1. Clinical Studies 6.1.2.2.1.1. Detailed Study Description 6.1.2.2.1.2. Study Results 6.1.2.2.1.3. Clinical Trials: Tabular View 6.1.2.3. Product Development Activities 6.1.2.3.1. Tabulated Product Summary 6.1.2.3.1.1. General Description Table 6.1.3. RBM 007: Ribomic 6.1.3.1. Product Description 6.1.3.1.1. Product Overview 6.1.3.1.2. Mechanism of Action 6.1.3.2. Research and Development 6.1.3.2.1. Clinical Studies 6.1.3.2.1.1. Detailed Study Description 6.1.3.2.1.2. Study Results 6.1.3.2.1.3. Clinical Trials: Tabular View 6.1.3.3. Product Development Activities 6.1.3.3.1. Tabulated Product Summary 6.1.3.3.1.1. General Description Table To be continued in the report………………………… 7. Recent Technologies 8. Achondroplasia Key Companies 8.1. Ascendis Pharma 8.2. BridgeBio Pharma/Novartis 8.3. BioMarin Pharmaceutical 8.4. Pfizer 8.5. Ribomic 9. Achondroplasia Key Products 9.1. TransCon CNP 9.2. Infigratinib 9.3. Vosoritide 9.4. Recifercept 9.5. TA 100 9.6. RBM 007 10. Dormant and Discontinued Products 10.1. Dormant Products 10.1.1. Reasons for being dormant 10.2. Discontinued Products 10.2.1. Reasons for the discontinuation 11. Achondroplasia - Unmet Needs 12. Achondroplasia - Future Perspectives 13. Appendix 14. Report Methodology 14.1. Secondary Research 14.2. Expert Panel Validation

TABLE 1 Diagnostic Guidelines TABLE 2 Treatment Guidelines TABLE 3 Assessment Summary TABLE 4 Company-Company Collaborations (Licensing / Partnering) Analysis TABLE 5 Achondroplasia Acquisition Analysis TABLE 6 Assessment by Phase of Development TABLE 7 Assessment by Product Type (Mono / Combination) TABLE 8 Assessment by Stage and Product Type TABLE 9 Assessment by Route of Administration TABLE 10 Assessment by Stage and Route of Administration TABLE 11 Assessment by Molecule Type TABLE 12 Assessment by Stage and Molecule Type TABLE 13 Assessment by MOA TABLE 14 Assessment by Stage and MOA TABLE 15 Late Stage Products (Phase-III) TABLE 16 Mid Stage Products (Phase-II) TABLE 17 Early Stage Products (Phase-I) TABLE 18 Pre-clinical and Discovery Stage Products TABLE 19 Inactive Products TABLE 20 Dormant Products TABLE 21 Discontinued Products Figure 1 Disease Overview Figure 1 History Figure 2 Symptoms Figure 3 Causes Figure 4 Pathophysiology Figure 5 Diagnostic Guidelines Figure 6 Treatment Guidelines Figure 7 Achondroplasia companies collaborations, Licensing, Acquisition –Deal Value Trends Figure 8 Company-Company Collaborations (Licensing / Partnering) Analysis Figure 9 Achondroplasia Acquisition Analysis Figure 10 Assessment by Phase of Development Figure 11 Assessment by Product Type (Mono / Combination) Figure 12 Assessment by Stage and Product Type Figure 13 Assessment by Route of Administration Figure 14 Assessment by Stage and Route of Administration Figure 15 Assessment by Molecule Type Figure 16 Assessment by Stage and Molecule Type Figure 17 Assessment by MOA Figure 18 Assessment by Stage and MOA Figure 19 Late Stage Products (Phase-III) Figure 20 Mid Stage Products (Phase-II) Figure 21 Early Stage Products (Phase-I) Figure 22 Pre-clinical and Discovery Stage Products Figure 23 Inactive Products Figure 24 Dormant Products Figure 25 Discontinued Products Figure 26 Unmet Needs

Ascendis Pharma BridgeBio Pharma Novartis BioMarin Pharmaceutical Pfizer Ribomic Rainier Therapeutics MorphoSys ProChon Biotech Novo Nordisk Novartis